Transcriptome Sequencing Reveals Key Pathways and Genes Associated with Cisplatin Resistance in Lung Adenocarcinoma A549 Cells

PLoS One. 2017 Jan 23;12(1):e0170609. doi: 10.1371/journal.pone.0170609. eCollection 2017.

Abstract

Acquired resistance to cisplatin-based chemotherapy frequently occurs in patients with non-small cell lung cancer, and the underlying molecular mechanisms are not well understood. The aim of this study was to investigate whether a distinct gene expression pattern is associated with acquired resistance to cisplatin in human lung adenocarcinoma. Whole-transcriptome sequencing was performed to compare the genome-wide gene expression patterns of the human lung adenocarcinoma A549 cisplatin-resistant cell line A549/DDP with those of its progenitor cell line A549. A total of 1214 differentially expressed genes (DEGs) were identified, 656 of which were upregulated and 558 were downregulated. Functional annotation of the DEGs in the Kyoto Encyclopedia of Genes and Genomes database revealed that most of the identified genes were enriched in the PI3K/AKT, mitogen-activated protein kinase, actin cytoskeleton regulation, and focal adhesion pathways in A549/DDP cells. These results support previous studies demonstrating that the pathways regulating cell proliferation and invasion confer resistance to chemotherapy. Furthermore, the results proved that cell adhesion and cytoskeleton regulation is associated with cisplatin resistance in human lung cancer. Our study provides new promising biomarkers for lung cancer prognosis and potential therapeutic targets for lung cancer treatment.

Publication types

  • Validation Study

MeSH terms

  • A549 Cells
  • Adenocarcinoma / genetics*
  • Adenocarcinoma / pathology
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / toxicity
  • Cisplatin / administration & dosage*
  • Cisplatin / toxicity
  • Drug Resistance, Neoplasm
  • Gene Expression Regulation, Neoplastic / genetics
  • Hep G2 Cells
  • Humans
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transcriptome / genetics*

Substances

  • Antineoplastic Agents
  • Cisplatin

Grants and funding

Shaanxi Lifegen Co. Ltd. provided support in the form of salary for one author, Qi Wang, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of Qi Wang is articulated in the "author contributions" section.